| A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1896 | 2016 |
| Assessment of PLSDA cross validation JA Westerhuis, HCJ Hoefsloot, S Smit, DJ Vis, AK Smilde, EJJ van Velzen, ... Metabolomics 4, 81-89, 2008 | 1583 | 2008 |
| Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients SN Ooft, F Weeber, KK Dijkstra, CM McLean, S Kaing, E van Werkhoven, ... Science translational medicine 11 (513), eaay2574, 2019 | 607 | 2019 |
| Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen, LA Smit, JM de Feijter, ... Nature medicine 26 (12), 1839-1844, 2020 | 343 | 2020 |
| Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality E Gogola, AA Duarte, JR de Ruiter, WW Wiegant, JA Schmid, R de Bruijn, ... Cancer cell 33 (6), 1078-1093. e12, 2018 | 298 | 2018 |
| Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022 | 276 | 2022 |
| Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs R Planells‐Cases, D Lutter, C Guyader, NM Gerhards, F Ullrich, DA Elger, ... The EMBO journal 34 (24), 2993-3008, 2015 | 252 | 2015 |
| T-profiler: scoring the activity of predefined groups of genes using gene expression data A Boorsma, BC Foat, D Vis, F Klis, HJ Bussemaker Nucleic acids research 33 (suppl_2), W592-W595, 2005 | 243 | 2005 |
| Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ... Scientific reports 6 (1), 1-13, 2016 | 205 | 2016 |
| Genome-wide analysis of yeast stress survival and tolerance acquisition to analyze the central trade-off between growth rate and cellular robustness A Zakrzewska, G Van Eikenhorst, JEC Burggraaff, DJ Vis, H Hoefsloot, ... Molecular biology of the cell 22 (22), 4435-4446, 2011 | 168 | 2011 |
| Statistical validation of megavariate effects in ASCA DJ Vis, JA Westerhuis, AK Smilde, J van der Greef BMC bioinformatics 8, 1-8, 2007 | 163 | 2007 |
| Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ... EMBO molecular medicine 7 (9), 1104-1118, 2015 | 158 | 2015 |
| Dynamic metabolomic data analysis: a tutorial review AK Smilde, JA Westerhuis, HCJ Hoefsloot, S Bijlsma, CM Rubingh, DJ Vis, ... Metabolomics 6, 3-17, 2010 | 121 | 2010 |
| Phenotyping tea consumers by nutrikinetic analysis of polyphenolic end-metabolites EJJ van Velzen, JA Westerhuis, JPM van Duynhoven, FA van Dorsten, ... Journal of proteome research 8 (7), 3317-3330, 2009 | 114 | 2009 |
| MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models Z Xue, DJ Vis, A Bruna, T Sustic, S van Wageningen, AS Batra, ... Cell research 28 (7), 719-729, 2018 | 113 | 2018 |
| Facilitating a culture of responsible and effective sharing of cancer genome data LL Siu, M Lawler, D Haussler, BM Knoppers, J Lewin, DJ Vis, RG Liao, ... Nature medicine 22 (5), 464-471, 2016 | 104 | 2016 |
| TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types N Aben, DJ Vis, M Michaut, LF Wessels Bioinformatics 32 (17), i413-i420, 2016 | 94 | 2016 |
| Multilevel models Improve precision and Speed of IC50 Estimates DJ Vis, L Bombardelli, H Lightfoot, F Iorio, MJ Garnett, LFA Wessels Pharmacogenomics 17 (7), 691-700, 2016 | 85 | 2016 |
| Identification of a druggable pathway controlling glioblastoma invasiveness N Pencheva, MC de Gooijer, DJ Vis, LFA Wessels, T Würdinger, ... Cell reports 20 (1), 48-60, 2017 | 77 | 2017 |
| Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with neratinib in the
JD Wulfkuhle, C Yau, DM Wolf, DJ Vis, RI Gallagher, L Brown-Swigart, ... JCO precision oncology 2, 1-20, 2018 | 53 | 2018 |
Lodewyk WesselsProfessor of Computational Cancer BiologyPatvirtintas el. paštas nki.nl
